



ASX RELEASE (2 AUGUST 2021)

## Appointment of New Directors

### Key Points:

- Dr Rob Jenny – experienced pharmaceutical executive – appointed an Executive Director under services agreement with Cannvalate
- Mr Simon Rowe – operational transformation and optimisation expert – appointed Non-Executive Director
- Dr Jenny and Mr Rowe join Chairman Steven Xu towards delivering on new corporate initiatives introduced by the Senior Executive Team of Epsilon

Epsilon Healthcare Limited (ASX:EPN) (Epsilon or the Company) is pleased to announce the appointment of two new directors of Epsilon, effective 1 August 2021. The new appointments bring significant experience to the Company across pharmaceuticals, research and development, operational optimisation, and supply chain logistics as the Company progresses towards being a toll and contract pharmaceutical manufacturer for the medicinal cannabis industry.

### **Dr Rob Jenny – Executive Director**

Dr Rob Jenny is currently an executive at Cannvalate – an Australian medicinal cannabis services company – where he manages their business development activities in the Australian and New Zealand market. Rob has previously held management and research roles including at Ensign Laboratories – one of Australia's largest contract pharmaceutical manufacturers – Immunoglobulin Group, and Monash University.

With respect to Rob's appointment through Cannvalate, the Company does not currently propose to remunerate Cannvalate or Rob at this time, with Rob's appointment through Cannvalate being strategically aligned towards Epsilon's corporate development in the near term. The Company will make further disclosures as to its agreement with Rob and Cannvalate as those terms are agreed.

### **Mr Simon Rowe – Non-Executive Director**

Mr Simon Rowe is currently the Supply Chain Transformation & Operations Leader ANZ at Kimberly-Clark – a Fortune 500 personal care company. Prior to that, Simon has held associate director and senior manager level roles within KPMG and EY advisory specialising in operational transformation and optimisation.

As a non-executive director, Simon will be remunerated from the non-executive director remuneration pool with no change in remuneration level from the previous non-executive directors of the Company.

Epsilon's Chairman, Steven Xu commented:

"I'm pleased to have both Dr Rob Jenny and Mr Simon Rowe join the Epsilon board bringing their combined wealth of relevant experience across pharmaceutical manufacturing, research and development, and operational transformation and optimisation as we look to significantly scale up Epsilon's core pharmaceutical contract and toll manufacturing operation at the Southport Facility in the near term.

"I look forward to working closely with both Dr Jenny and Mr Rowe towards the achievement of the corporate strategic initiatives set out by our Senior Management Team – led by the Group Chief Executive Officer and Chief Operating Officer."

For further information, please contact:



**Jarrold White**

Group Chief Executive Officer

e: [ceo@epsilonhc.com](mailto:ceo@epsilonhc.com)

**Sonny Didugu**

Group Chief Operating Officer

e: [coo@epsilonhc.com](mailto:coo@epsilonhc.com)

**Steven Xu**

Non-Exec Chairman

e: [corporate@epsilonhc.com](mailto:corporate@epsilonhc.com)

ASX release authorised by the Board of Directors.

**Epsilon Healthcare Limited (ASX: EPN) – [epsilonhelthcare.com.au](http://epsilonhelthcare.com.au)**

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic group, and the Medimar Platform. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.